Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 8:25 pm Sale | 2024-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | Forward Ventures V, LP | 847,600 4.300% | -1,719,922 (-66.99%) | Filing History |
| 2024-11-14 4:33 pm Sale | 2024-09-30 | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -3,833,785 (Position Closed) | Filing History |
| 2024-02-13 9:04 pm Sale | 2023-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | Forward Ventures V, LP | 2,567,522 6.650% | -97,268 (-3.65%) | Filing History |
| 2023-02-13 5:53 pm Purchase | 2022-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND L P | 3,833,785 9.980% | 102,041 (+2.73%) | Filing History |
| 2023-01-10 5:21 pm Unchanged | 2022-06-08 | 13D | Viracta Therapeutics, Inc. VIRX | Schindel Yair Chaim | 7,392,237 19.350% | 0 (Unchanged) | Filing History |
| 2022-07-08 4:56 pm Sale | 2022-06-30 | 13G | Viracta Therapeutics, Inc. VIRX | BlackRock Inc. BLK | 542,431 1.400% | -1,826,487 (-77.10%) | Filing History |
| 2022-02-15 1:48 pm Purchase | 2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | Laurence W. Lytton | 255,876 0.700% | 255,876 (New Position) | Filing History |
| 2022-02-14 1:33 pm Purchase | 2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND L P | 3,731,744 9.900% | 3,731,744 (New Position) | Filing History |
| 2022-02-14 12:14 pm Purchase | 2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | Aisling Capital IV LP | 288,571 0.770% | 288,571 (New Position) | Filing History |
| 2022-02-09 5:24 pm Purchase | 2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | Forward Ventures V, LP | 2,664,790 7.140% | 42,516 (+1.62%) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX | BlackRock Inc. BLK | 2,368,918 6.300% | 2,368,918 (New Position) | Filing History |
| 2021-03-10 9:40 pm Unchanged | 2020-08-11 | 13D | Viracta Therapeutics, Inc. VIRX | New Enterprise Associates 12 Limited Partnership | 0 0.000% | 0 (Unchanged) | Filing History |
| 2021-03-08 5:05 pm Purchase | 2021-02-25 | 13G | Viracta Therapeutics, Inc. VIRX | Forward Ventures V, LP | 2,622,274 7.090% | 2,622,274 (New Position) | Filing History |
| 2021-03-05 1:30 pm Purchase | 2021-02-25 | 13G | Viracta Therapeutics, Inc. VIRX | LVP LIFE SCIENCE VENTURES III L.P. | 3,124,094 8.440% | 3,124,094 (New Position) | Filing History |
| 2021-03-02 06:14 am Purchase | 2021-02-24 | 13D | Viracta Therapeutics, Inc. VIRX | Schindel Yair Chaim | 7,392,237 19.980% | 7,392,237 (New Position) | Filing History |
| 2021-02-16 3:50 pm Unchanged | 2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS | CAXTON CORP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2021-02-16 11:06 am Sale | 2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS | Ayrton Capital LLC | 0 0.000% | -10,869,565 (Position Closed) | Filing History |
| 2021-02-16 09:50 am Unchanged | 2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS | CVI Investments, Inc. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2021-02-16 06:24 am Unchanged | 2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS | Nantahala Capital Management, LLC | 0 0.000% | 0 (Unchanged) | Filing History |
| 2021-02-12 6:47 pm Purchase | 2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS | BIOTECHNOLOGY VALUE FUND L P | 1,814,308 9.980% | 1,814,308 (New Position) | Filing History |